Sitagliptin/metformin

Sitagliptin/metformin
Combination of
SitagliptinDipeptidyl peptidase-4 inhibitor
MetforminBiguanide
Clinical data
Trade namesJanumet, Januet, others
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Sitagliptin/metformin, sold under the brand name Janumet among others, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes.[9] It may be used in those whose blood sugar is not controlled with metformin and a sulfonylurea.[9][10] It is taken by mouth.[9]

Common side effects include diarrhea, headache, and upper respiratory tract infections.[5] Serious side effects may include lactic acidosis, pancreatitis, low blood sugar, heart failure, joint pain, and allergic reactions.[5] It has not been properly studied in women who are pregnant or breastfeeding.[1] It contains sitagliptin (a dipeptidyl peptidase-4 inhibitor) and metformin (a biguanide).[5]

The combination was approved for medical use in the United States in 2007.[5] In 2021, it was the 154th most commonly prescribed medication in the United States, with more than 3 million prescriptions.[11][12] It is available as a generic medication.[13][14]

  1. ^ a b "Metformin / sitagliptin Use During Pregnancy". Drugs.com. Archived from the original on 19 April 2019. Retrieved 19 April 2019.
  2. ^ "Sitagliptin/metformin Sandoz XR (Sandoz Pty Ltd)". Therapeutic Goods Administration (TGA). 2 June 2023. Retrieved 10 September 2023.
  3. ^ "Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.
  4. ^ "Janumet 50 mg/1000 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 25 November 2020. Archived from the original on 26 October 2020. Retrieved 5 December 2020.
  5. ^ a b c d e Cite error: The named reference Janumet FDA label was invoked but never defined (see the help page).
  6. ^ Cite error: The named reference Janumet XR FDA label was invoked but never defined (see the help page).
  7. ^ Cite error: The named reference Janumet EPAR was invoked but never defined (see the help page).
  8. ^ "Efficib EPAR". European Medicines Agency. 16 July 2008. Retrieved 25 July 2024.
  9. ^ a b c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 682. ISBN 9780857113382.
  10. ^ Hayes J, Anderson R, Stephens JW (2016). "Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy". Drug Design, Development and Therapy. 10: 2263–70. doi:10.2147/DDDT.S93076. PMC 4958358. PMID 27486305.
  11. ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  12. ^ "Metformin; Sitagliptin - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
  13. ^ "Sitagliptin / Metformin hydrochloride Accord EPAR". European Medicines Agency (EMA). 17 May 2022. Archived from the original on 3 August 2022. Retrieved 3 August 2022.
  14. ^ "Sitagliptin / Metformin hydrochloride Sun: Pending EC decision". European Medicines Agency (EMA). 26 January 2023. Archived from the original on 27 January 2023. Retrieved 28 January 2023.